Boston to host HIV vax conference in 2012; CDC: Adult vax rates slipped in 2009;

Vaccine Research 

> Physician-scientists from Weill Cornell Medical College and Columbia University Medical Center are enrolling patients with non-small cell lung cancer at New York-Presbyterian Hospital as part of an ongoing Phase III trial. Release

> Boston will host the world's largest conference on HIV vaccine research in 2012. Story

> NanoBio Corporation landed a $6M grant from the Bill & Melinda Gates Foundation to support the development of an intranasal vaccine for Respiratory Syncytial Virus. NanoBio release

> A new discovery may explain why a tuberculosis vaccine is not as effective for some people as anticipated, and potentially explains why other vaccines do not work as well for some as they do for others. In a research report presented in the December 2010 issue of the Journal of Leukocyte Biology, scientists from Singapore show that Mycobacterium chelonae, a common environmental bacterium found in soil and water, can decrease the effectiveness of the bacille Calmette-Guerin vaccine used to prevent tuberculosis, especially in countries outside of the United States. Release

> Tolerx has won $1.5 million from the Cancer Vaccine Acceleration Fund to finance work on a new therapy that bolsters the human immune system to fight off cancer. Story

Vaccine Market 

> The CDC says that adult vaccination rates in the U.S. slipped in 2009 and experts are calling on the nation's doctors to help reverse the trend. Story

> With the global economic crunch cutting into the amount of donations available for vaccine campaigns, the Global Alliance for Vaccine Immunization is creating an advocacy group that will attempt to raise $3.7 billion for the work. Report

> GAVI says that a emerging market vaccine manufacturer will help significantly cut the cost of a 5-in-1 vaccine that is used around the world. Story

> GlaxoSmithKline has teamed up with another emerging markets partner. The drugmaker inked a deal with Russian vaccine firm JSC Binnopharm to make and sell several of its big vaccines in that country. Report

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.